LipoScience, provider of a proprietary test for assessing the risk of heart disease, postponed its IPO on Tuesday due to market conditions. The Raleigh, NC based company had planned to offer 5 million shares at a range of $14-$16. Merrill Lynch was the lead manager for this deal.
